Egypt Edition 
MENA+ Edition 
UAE Edition 
Saudi Edition 
AI + Innovation (MENA) 
Logistics (MENA) 
GSK Egypt rejects Acdima’s bid to start due diligence, closing the door to a sale
GlaxoSmithKline Egypt’s board of directors has rejected a request submitted by Acdima to start due diligence on the company, GSK…
What we’re tracking on 15 March 2021
Good morning, friends, and welcome to another brisk news day in which M&A news takes a back seat to the…
GSK is staying put — for now
GSK puts Egypt exit on the backburner: GlaxoSmithKline has shelved plans to sell its units in Egypt and Tunisia following…
GSK, Hikma end acquisition talks
Hikma Pharma won’t be acquiring GlaxoSmithKline’s Egypt unit: GSK and Hikma Pharma have agreed to end talks over a takeover…
Strong with the force, healthcare M&As are
The latest M&A activity in the red-hot healthcare sector appears to be a bidding war brewing for Alexandria Medical Services.…
GSK only has eyes for Hikma
GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with…
Rameda throws its hat in the ring for GSK’s Egypt business
Ladies and gentlemen, we have a good, old-fashioned bidding war: Rameda Pharma is the latest to show interest in GlaxoSmithKline's…
A bidding war for GSK’s Egyptian arm?
Acdima may have just touched off a bidding war for GlaxoSmithKline's Egypt business, according to a regulatory filing (pdf) yesterday,…
Something went wrong. Please refresh the page and/or try again.